Based on the in silico results of the 144 mRNAs summarized here, whose differential expression has already been validated in patients, we propose a protein-coding gene expression profile composed of MYC, PTEN, TNF, STAT3, BCL2, FN1, TGFB1, CCND1, EGF, IL1B, CD44, KRAS, KLK3, PTEN, AR, ERG, AMACR, IL2, PGR, HSPB1, FOLH1, BIRC5, PSCA, SLC22A3, and ABCC10, to be used in the clinical diagnosis of prostate cancer. This evidence concerns the gene IL2 and Familial prostate cancer.